SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
This comparative effectiveness study found that initiation of SGLT2i vs GLP-1RA treatment in individuals with type 2 diabetes was associated with a lower 5-year risk of CKD and a lower 5-year count of AKI. These findings underscore the potential of SGLT2i treatment for primary prevention of kidney disease in individuals with type 2 diabetes.
Authors
- Christian Fynbo Christiansen (ORCID: https://orcid.org/0000-0002-0727-953X)
- Ina Trolle Andersen (ORCID: https://orcid.org/0000-0002-8140-1548)
- Simon Kok Jensen (ORCID: https://orcid.org/0000-0002-0032-131X)
- U. Heide-Jørgensen
- Kasper Bonnesen (ORCID: https://orcid.org/0000-0002-8626-2372)
- Edouard L Fu
- Reimar W. Thomsen
Institutions
- Aarhus University (DK)
- Leiden University Medical Center (NL)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Karolinska Institutet (SE)
- North Denmark Region (DK)
- Regionshospitalet Viborg (DK)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1001/jamainternmed.2025.7409
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 30.73